Genetic testing

Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

Retrieved on: 
Thursday, October 13, 2022
Health, LinkedIn, Disease, Risk, Diagnosis, ASD, Machine learning, Patient, Data, Research, SMFR, Twitter, Instagram, Pediatrics, Annual general meeting, Simons Foundation Autism Research Initiative, Autism spectrum, Disorder, Epilepsy, AI, Autism, Genetic testing, CNS, American Academy, GLOBE, American Academy of Pediatrics, SFARI, Child, GeneDx, Gene, Pharmaceutical industry, Vaccine, Medical device, Facebook

STAMFORD, Conn., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, is presenting research today on autism spectrum disorders (ASD) at the Child Neurology Society (CNS) Annual Meeting. The research underscores the positive outcomes of exome analysis for individuals with ASD, supporting the use of a broader genetic testing approach to reach a faster diagnosis. This study of almost 19,000 individuals is one of the few to examine the genetic basis of autism and current guidelines around screening and testing.

Key Points: 
  • This study of almost 19,000 individuals is one of the few to examine the genetic basis of autism and current guidelines around screening and testing.
  • The study evaluated exome analysis for individuals with ASD against current testing methods and provided proof points that exome sequencing should be a first-tier test for ASD.
  • The median ages at testing in this analysis were 6.4 and 8.4 years for both isolated and syndromic ASD; exome sequencing provided higher diagnostic rates of 7.9-21%.
  • Additionally, this study revealed a high number of emerging genes not previously connected to autism.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, October 12, 2022
Remuneration, Anti-Kickback Statute, Medtronic, Reward, NASDAQ, Federal, Defendant, Q2, Lists of schools in England, Federation, News, Risk assessment, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SMFR, Investment, Justice, Company, Battle of Saint-Fulgent, PLTR, Genetic testing, GLOBE, Insulin, Disclosure, FDA, U.S. Department of Defense Strategy for Operating in Cyberspace, Genetics, Risk, Government, Growth, War, Intelligence, Research, Workforce, U.S. Department of Justice Office of Legislative Affairs, Stark Law, Physician, U.S. Securities and Exchange Commission, SEC, Complaint, Patient, EPS, Food, Medicare, Diabetes, COVID-19, Health, Pharmaceutical industry, Audit, Medical device, Dietary supplement, Renewable energy, Risk management, Palantir Technologies, P.C

For more information on the Sema4 class action go to: https://bespc.com/cases/SMFR

Key Points: 
  • For more information on the Sema4 class action go to: https://bespc.com/cases/SMFR
    Medtronic is a medical device company.
  • On February 7, 2020, the FDA classified Medtronics November 2019 notification as a Class I recallthe most serious type of recall.
  • For more information on the Fulgent class action go to: https://bespc.com/cases/FLGT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, LinkedIn, Annals of Neurology, Platform, Prevalence, Hospital, Population, Diagnosis, Ambit, Epilepsy, NASDAQ, Patient, Duke Energy Center for the Performing Arts, Dees, Lists of diseases, Twitter, Neuroscience, Precision medicine, Degenerative disease, Awareness, Genetic testing, CNS, UCSF Benioff Children's Hospital, GLOBE, Brain, DEE, Duke Energy Center, Movement disorders, Central nervous system disease, UCSF, Leadership, Pharmaceutical industry, Neurology, Praxis

Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs.

Key Points: 
  • Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs.
  • "Ambit's methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population."
  • Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting.
  • Ambit Inc. is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease.

Family Heart Foundation Study Shows Some Children With Homozygous Familial Hypercholesterolemia Miss out on Decades of Life-Saving Treatment

Retrieved on: 
Tuesday, October 11, 2022
Research, Children, Cardiology, Philanthropy, Health, Consumer, General Health, Foundation, Science, People, AAP, Degenerative disease, Risk, FH, Life, Conference, Diagnosis, Hypercholesterolemia, Patient, Research, Exhibition, Serum, National Conference, Genetic testing, American Academy, Pediatrics (journal), Cascade, Pharmaceutical industry

The data raises the possibility that only children with the most severe cases of HoFH are being diagnosed early.

Key Points: 
  • The data raises the possibility that only children with the most severe cases of HoFH are being diagnosed early.
  • In addition, others who may have somewhat lower LDL-C are not identified early and miss out on decades of life-saving treatment, which could lead to heart disease earlier in life.
  • HoFH, a rare genetic condition characterized by extremely elevated levels of serum LDL-C, affects both children and adults.
  • There are two forms of FH: Heterozygous Familial Hypercholesterolemia and Homozygous Familial Hypercholesterolemia.

Genetic Testing Global Market Research Report 2022 Featuring Major Players - Abbott Laboratories, Bio-Rad Laboratories, Eurofins Scientific, F. Hoffmann-La Roche, & Illumina - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Health, Genetics, Lists of diseases, Genetics, Sale, Risk, Anti-transglutaminase antibodies, Prevalence, Growth, Diagnosis, Asia-Pacific, Organization, Genetic testing, Patient, National Center for Biotechnology Information, Exact sciences, Thalassemia, Cancer, Cystic fibrosis, Degenerative disease, Genetic disorder, Technology, Duchenne muscular dystrophy, Acquisition, National Center for Integrative Biomedical Informatics, Alzheimer's disease, Protein, Huntington's disease, DNA, Chromosome, COVID-19, Gene, Vaccine

The main types of genetic testing are predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and other types.

Key Points: 
  • The main types of genetic testing are predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, nutrigenomic testing, and other types.
  • The rising prevalence of genetic disorders is expected to propel the growth of the genetic testing market going forward.
  • Major companies operating in the genetic testing market are focused on developing technology to sustain their position in the market.
  • The countries covered in the genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Kindbody's Nationwide Expansion Continues with Opening of Houston Clinic

Retrieved on: 
Tuesday, October 11, 2022
National Institutes of Health, Adoption, Reproductive health, Emory University, Walter Reed National Military Medical Center, Parent, Education, Gynaecology, Patient, Restaurant, NIH, Research, Program, Corporation, GV (company), University, MedStar Georgetown University Hospital, National, Society, CEO, IVF, Genetic testing, Fertility, Howard Hughes Medical Institute, Infertility, Uterine fibroid, Heart, Obstetrics, Fertility preservation, Medicine

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody, a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX. Kindbody Houston was built to meet the growing demand for comprehensive fertility and family-building benefits by employers in the area, which has experienced record job growth with its thriving local economy. Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology. Dr. Parikh is currently accepting patients. The opening marks the company's second location in Texas which is also home to Kindbody Austin. A third Texas location will launch in Dallas later this year.

Key Points: 
  • NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody , a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX.
  • Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology.
  • The opening marks the company's second location in Texas which is also home to Kindbody Austin.
  • "We're excited to bring Kindbody's mission of accessible, high-quality fertility care to Houston employers and the entire community," said Annbeth Eschbach, CEO, Corporate of Kindbody.

CCRM Fertility Grows its Award-Winning Team of Physicians in New York

Retrieved on: 
Tuesday, October 11, 2022
Physician, Reproductive health, Yale University, History of medicine, Medicine, Obstetrics, Health care, Woman, Science, Hope, Joseph, Education, Reproductive biology, NYU, Gynaecology, New York University Grossman School of Medicine, Patient, Emil Steinberger (endocrinologist), Research, Reproductive rights, Multimedia, Albert Einstein College of Medicine, NEW, Columbia University, Reproduction, Young professional, Reproductive technology, CEO, Awareness, Arnold, IVF, Fertility, Genetic testing, Journal, Infertility, Endocrinology, View, Birth control, Pharmaceutical industry, Genetics

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, expands its New York team with the addition of Dr. Arielle Bayer. She is board certified in obstetrics and gynecology, and board-eligible in reproductive endocrinology and infertility. A New York City native, Dr. Bayer is now accepting new patients at CCRM Fertility in New York.

Key Points: 
  • A New York City native, Dr. Bayer is now accepting new patients at CCRM Fertility in New York.
  • "With Dr. Bayer joining our acclaimed group of physicians, we can help even more families in New York achieve their family-building goals," said Jon Pardew, president and CEO of CCRM Fertility.
  • "Her compassion for patients and outstanding clinical acumen will have an immediate impact on patients seeking high quality fertility treatments."
  • CCRM Fertility in New York is located at 810 7th Ave., 21st Floor, New York, NY 10019.

FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
Tuesday, October 11, 2022
Physician, Genetics, Remuneration, News, Office of Inspector General, U.S. Department of Health and Human Services, Anti-Kickback Statute, SEC, Reward, Advertising, NASDAQ, Patient, Labour government, Court, Investment, Company, NEW, Justice, U.S. Department of Justice Office of Legislative Affairs, Battle of Saint-Fulgent, Medicare, District court, Stark, Lists of schools in England, Securities Exchange Act of 1934, Genetic testing, GLOBE, Central District, Lists of action films, The Legal 500, Disclosure, COVID-19, Stark Law, Health, Tobacco, Pharmaceutical industry, Online gambling, Security (finance)

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • If you purchased Fulgent securities, and/or would like to discuss your legal rights and options please visit Fulgent Genetics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Thermo Fisher Scientific Launches CE-IVD Marked Panel to Detect Most Common Gastrointestinal Bacteria

Retrieved on: 
Monday, October 10, 2022
Research, Medical Devices, Infectious Diseases, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, PPD, Applied Biosystems, Thermo Fisher Scientific, Patheon, Infection, Science, Salmonella, Laboratory, Solution, Fisher Scientific, Patient, Genetic testing, Campylobacter, IVDD, Research, Campylobacter coli, Mindful Scientific Inc., Technology, PCR, Campylobacter jejuni, Health, West Pharmaceutical Services explosion, Bacteria, CE, Genetic, Campylobacter upsaliensis, EIEC, Invitrogen, Vaccine, Fine chemical

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel , a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TaqPath Enteric Bacterial Select Panel , a CE-IVD marked panel designed to detect common gastrointestinal (GI) bacteria and help enable clinicians to identify the root cause of an infection and administer the most appropriate treatment to their patients more quickly.
  • The new test leverages polymerase chain reaction (PCR) technology to analyze stool samples for a range of common GI bacteria, including Salmonella spp.
  • For more information on the TaqPath Enteric Bacterial Select Panel, please visit www.thermofisher.com/taqpathentericselect
    The TaqPath Enteric Bacterial Select Panel is CE marked, For In Vitro Diagnostic Use.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

FLGT Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Fulgent Genetics, Inc. of Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Monday, October 10, 2022
Physician, Remuneration, Genetics, News, Insurance, Office of Inspector General, U.S. Department of Health and Human Services, SEC, Reward, NASDAQ, Patient, Anti-Kickback Statute, COPY, Justice, U.S. Department of Justice Office of Legislative Affairs, Battle of Saint-Fulgent, Medicare, District court, Stark, Genetic testing, GLOBE, Central District, Fraud, Disclosure, LLP, COVID-19, Stark Law, Health, Lead, Private investigator, Pharmaceutical industry, Architecture

The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.

Key Points: 
  • The action charges Fulgent with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects.
  • Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.